Shares of Dialysis Services Providers Soar as Novo Nordisk’s Ozempic Falls Short in Kidney Disease Patients
Shares of Dialysis Service Providers Surge on Novo Nordisk’s Diabetes Drug Results By [Editor’s Name] (City, Date) – Dialysis services providers experienced significant gains in their shares, ranging from 3% to 12%, following new data related to Novo Nordisk’s widely popular diabetes drug, Ozempic. This information suggests a less-than-expected impact on chronic kidney disease patients. … Read more